Cogent Biosciences, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Cogent Biosciences, Inc. (COGT) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $5.92 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-14
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $5.92M.
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$820.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month |
|---|---|
| 2018-03-31 | $5.92M 10-Q · filed 2018-05-14 |
| 2017-03-31 | -$820.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |